NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. by Sancho, Patrícia et al.
NADPH Oxidase NOX4 Mediates Stellate Cell Activation
and Hepatocyte Cell Death during Liver Fibrosis
Development
Patricia Sancho1, Je`ssica Mainez1, Eva Crosas-Molist1, Ce´sar Roncero2, Conrado M. Ferna´ndez-
Rodriguez3, Fernando Pinedo4, Heidemarie Huber5, Robert Eferl5,6, Wolfgang Mikulits5,
Isabel Fabregat1,7*
1 Biological Clues of the Invasive and Metastatic Phenotype Group, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet, Barcelona, Spain, 2Departamento de
Bioquı´mica y Biologı´a Molecular II, Facultad de Farmacia, Universidad Complutense and Instituto de Investigacio´n Sanitaria del Hospital Clı´nico San Carlos (IdISSC), Madrid,
Spain, 3 Service of Gastroenterology, Hospital Universitario Fundacio´n Alcorco´n and Universidad Rey Juan Carlos, Alcorco´n, Madrid, Spain, 4Unit of Pathology, Hospital
Universitario Fundacio´n Alcorco´n, Alcorco´n, Madrid, Spain, 5Department of Medicine I, Division: Institute of Cancer Research, Medical University of Vienna, Vienna,
Austria, 6 Ludwig Boltzmann Institute for Cancer Research (LBI-CR), Vienna, Austria, 7Department of Physiological Sciences II, University of Barcelona, Barcelona, Spain
Abstract
A role for the NADPH oxidases NOX1 and NOX2 in liver fibrosis has been proposed, but the implication of NOX4 is poorly
understood yet. The aim of this work was to study the functional role of NOX4 in different cell populations implicated in
liver fibrosis: hepatic stellate cells (HSC), myofibroblats (MFBs) and hepatocytes. Two different mice models that develop
spontaneous fibrosis (Mdr22/2/p19ARF2/2, Stat3Dhc/Mdr22/2) and a model of experimental induced fibrosis (CCl4) were
used. In addition, gene expression in biopsies from chronic hepatitis C virus (HCV) patients or non-fibrotic liver samples was
analyzed. Results have indicated that NOX4 expression was increased in the livers of all animal models, concomitantly with
fibrosis development and TGF-b pathway activation. In vitro TGF-b-treated HSC increased NOX4 expression correlating with
transdifferentiation to MFBs. Knockdown experiments revealed that NOX4 downstream TGF-b is necessary for HSC
activation as well as for the maintenance of the MFB phenotype. NOX4 was not necessary for TGF-b-induced epithelial-
mesenchymal transition (EMT), but was required for TGF-b-induced apoptosis in hepatocytes. Finally, NOX4 expression was
elevated in patients with hepatitis C virus (HCV)-derived fibrosis, increasing along the fibrosis degree. In summary, fibrosis
progression both in vitro and in vivo (animal models and patients) is accompanied by increased NOX4 expression, which
mediates acquisition and maintenance of the MFB phenotype, as well as TGF-b-induced death of hepatocytes.
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Introduction
Liver fibrosis is the final consequence of many chronic liver
injuries [1]. Hepatic stellate cells (HSCs) are activated to
myofibroblasts (MFBs), which are mainly responsible for collagen
deposition during hepatic fibrogenesis. Once injured, hepatocytes
undergo apoptosis. The transforming growth factor-beta (TGF-b),
whose levels increase during the development of liver fibrosis,
could be involved in both processes [2]. Thus, TGF-b inhibits
growth and induces apoptosis of hepatocytes and also contributes
to the activation of HSCs [3,4].
The generation of reactive oxygen species (ROS) plays relevant
roles in hepatic fibrosis and recent works point to NADPH
oxidases (NOX) as a key source of ROS in the fibrotic liver [5].
Two NOX isoforms, NOX1 and NOX2, mediate pro-fibrogenic
effects in endogenous liver cells [6,7,8]. However, less is known
about the possible role in liver fibrosis of another isoform, NOX4,
which is highly expressed in hepatocytes and HSCs [8]. We
previously reported that NOX4 mediates TGF-b-induced apop-
tosis in hepatocytes in primary culture [9] and causes ROS
production upon the in vitro transdifferentiation of activated HSCs
to MFBs [3]. In other fibrotic models, NOX4 accounts for ROS-
induced fibroblast and mesangial cell activation, playing an
essential role in TGF-b1-mediated fibroblast differentiation into
a profibrotic myofibroblast phenotype and matrix production [10].
Indeed, TGF-b induces NOX4 expression in lung mesenchymal
cells, which mediates MFB activation and fibrogenic responses to
lung injury [11]. In this same line of evidence, ROS signaling by
NOX4 is required for TGF-b-induced differentiation of fibroblasts
into MFB in heart [12], kidney [13] and diseased prostatic stroma
[14].
The aim of this work was to analyze whether NOX4 expression
is modulated in experimental animal models of liver fibrosis and
during the development of human liver fibrogenesis. We
demonstrate that NOX4 expression increases in parallel to liver
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fibrotic processes and may be required for TGF-b-induced
activation of HSC and for the maintenance of the MFB
phenotype. In hepatocytes, NOX4 causes cell death but does
not mediate epithelial-mesenchymal transition (EMT). These
results open new perspectives for the involvement of NOXes in
liver fibrosis and for the potential development of new therapeutic
targeted tools.
Materials and Methods
Ethics statement
Mice were housed in accordance with European laws and with
the general regulations specified by the Good Scientific Practices
Guidelines of the Medical University of Vienna. From Spain, the
approval for all the experiments related to the study of liver fibrosis
in experimental animal models was applied to the General
Direction of Environment and Biodiversity, Government of
Catalonia, and approved with the number #4589, 2011
(document enclosed). Human tissues were collected with the
required approvals from the Institutional Review Board (Comite´
E´tico de Investigacio´n Clı´nica del Hospital Universitario Funda-
cio´n Alcorco´n) and patient’s written consent conformed to the
ethical guidelines of the 1975 Declaration of Helsinki (both
documents are enclosed).
Reagents and antibodies
TGF-b was from Merck (Darmstadt, Germany). Fetal bovine
serum was from Sera Laboratories International (Cinder Hill,
UK). Glutathione-ethyl-ester (GEE), Diphenyleneiodonium chlo-
ride (DPI) and Butylated hydroxyanisole (BHA) were from Sigma
(St Louis, USA). The caspase-3 substrate Ac-DEVD-AMC was
from Pharmingen (San Diego, CA, USA). Antibodies: mouse anti-
b-actin (clone AC-15, Sigma), rabbit anti-cleaved caspase-3 (Asp-
175) from Cell Signaling Technology (Danvers, MA, USA), anti-
F4/80 (Abcam, Cambridge, UK), mouse anti-E-cadherin (BD
Pharmingen, NJ, USA), rabbit anti-ki67 (Abcam), mouse anti-
NOX2 (Santa Cruz Biotechnology, CA, USA), anti-NOX4 raised
by Sigma-Genosys against a peptide corresponding to the C-
terminal loop region (aminoacids 499–511), mouse anti-a-SMA
(Sigma, St Louis, USA), rabbit anti-phospho-Smad2 (Ser465/467)
and rabbit anti-phospho-Smad3 (Ser423/425) from Cell Signaling
Technology, goat anti-Smad2/3, anti-Smad7 and anti-TGF-b
from Santa Cruz Biotechnology and mouse anti-vimentin (Sigma,
St Louis, USA).
Mice
Three animal experimental models of liver fibrosis were used for
this study: two genetically modified mice and one drug-induced
model. Mdr22/2/p19ARF2/2 double null mice [15] displayed a
fibrotic phenotype comparable to Mdr22/2 mice, widely used as a
model for experimental liver fibrosis [16,17], characterized by
severe hepatic injury and large periductal accumulation of MFBs,
but showed the additional advantage of allowing the isolation of
immortal cells for in vitro experiments [15]. Stat3Dhc/Mdr22/2
mice show Stat3 conditional inactivation specifically in hepato-
cytes and cholangiocytes in a Mdr22/2 background [18], which
strongly aggravates liver injury and fibrosis. Animals were
sacrificed to evaluate liver histology at 2 and 7 weeks of age.
C.B-17/IcrHsd-Prkcdscid (SCID) mice have been used as control.
For CCl4 experiments, CCl4 (Sigma, St Louis, USA) was diluted
1:4 in ultrapure Olive Oil (Sigma, St Louis, USA) and injected
intraperitoneally at a concentration of 1.5 mg per gram of body
weight into 3-month old C57BL/6J mice. The treatment was
performed two times a week for 6 weeks to induce hepatic fibrosis.
Mice were sacrificed 3 days after the last injection and liver
samples were collected and processed for immunohistochemical
analysis.
Cell models and cell culture conditions
No commercial cell lines have been used in this study. Mice
stellate cells, myofibroblasts and hepatocytes were obtained in our
or colleagues’ laboratories and used in previous published works
[14,18,19]: 1) By employing p19ARF deficiency, we established a
non-transformed murine HSC model to investigate their plasticity
and the dynamics of HSC activation [19]. The immortal cell line,
referred to as M1-4HSC, showed stellate cell characteristics
including the expression of desmin, glial fibrillary acidic protein,
alpha-smooth muscle actin and pro-collagen I [19]. Treatment of
these non-tumorigenic M1-4HSC with pro-fibrogenic TGF-b1
provoked a morphological transition to a myofibroblastoid cell
type which was accompanied by enhanced cellular turnover and
impaired migration [19]. These cells have been used in this study
to analyze the role of NOX4 in the in vitro activation of HSC to
MFB; 2) In vivo-activated MFBs derived from physiologically
inflamed livers of Mdr2/p19ARF double-null mice were obtained
as previously described [15] and used in this study in in vitro
experiments to analyze the role of NOX4 in maintaining the
myofibroblast phenotype; 3) Finally, hepatocytes from wild-type
mice were isolated and immortalized with a puromycin-resistance
retroviral vector pBabe encoding Simian virus 40 large T antigen
(LTAg), as described [20] and were generously provided by Dr.
AM Valverde (Madrid, Spain). These cells were used in this study
to analyze the potential role of NOX4 in the TGF-b-induced
effects related to fibrosis development, i.e., epithelial-mesenchymal
transitions and apoptosis. For cell culture, cells were grown in
DMEM (Lonza, Basel, Switzerland) supplemented with 10% FBS
and maintained in a humidified atmosphere of 37uC, 5% CO2.
Human samples
Biopsies from 28 chronic hepatitis C virus (HCV) patients
showing different degrees of fibrosis or control liver samples
extracted in surgeries from colorectal cancer patients with hepatic
metastasis were collected in the Hospital Universitario de Alcorco´n
(Madrid, Spain). The control group was formed by 10 patients in
whom liver biopsy was performed by altered function test. Liver
biopsy examination revealed normal histology or minimal change.
Immunohistochemistry and immunocytochemistry
studies
For immunohistochemistry, sections of 4 mm-thick paraffin-
embedded livers were stained with hematoxylin and eosine (H&E)
or Trichrome (Sigma) for collagen staining using standard
procedures. The immunostaining was performed by incubating
primary antibodies (diluted from 1:50 to 1:100) overnight at 4uC
and by visualization with the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA). Immunocytochemistry studies
were performed as described previously [21]. Representative
images were taken with a Spot 4.3 digital camera and edited in
Adobe Photoshop. Cells were visualized in an Olympus BX-60
with the appropriate filters.
Analysis of cell number
Cell number was analyzed after crystal violet staining [4].
Total ROS production
Intracellular ROS content was measured by staining with the
fluorescent probe H2DCF-DA as described previously [22].
Role of NOX4 in Liver Fibrosis
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Analysis of caspase-3 activity
Caspase-3 activity was analyzed fluorimetrically upon incuba-
tion of 20 mg of cell lysates with 6.6 mg/mL Ac-DEVD-AMC for
2 hours at 37uC [22]. Results are calculated as units of caspase-3
activity per microgram of protein per hour.
Analysis of gene expression
RNeasy Mini Kit (Qiagen, Valencia, CA, USA) was used for
total RNA isolation. Reverse transcription (RT) was carried out
using the High Capacity Reverse Transcriptase kit (Applied
Biosystems, Foster City, CA, USA), and 500 ng of total RNA from
each sample for complementary DNA synthesis. PCR products in
semiquantitative reactions were obtained after 30–35 cycles of
amplification at annealing temperatures of 57–62uC, and analyzed
by 1.5% agarose gel electrophoresis. Expression of 18S was
analyzed as a loading control, as indicated. The –RT channel
contained RNA that had not been treated with the RT mixture.
For Real-Time quantitative PCR, expression levels were
determined in duplicate in an ABIPrism7700 System, using the
SybrH Green PCR Master Mix (Applied Biosystems).
All the primers used for both semiquantitative PCR or Real-
Time quantitative PCR reactions are listed in Suppl. Table 1 and
2, respectively.
Western blot analysis
Total protein extracts and Western Blot procedure were carried
out as previously described [22,23]. Antibodies were used at
1:1000, except b-actin (1:3000). Protein concentration was
measured with the BCATM Protein Assay kit (Pierce, Rockford,
USA).
Knock-down assays
Cells at 70% confluence were transiently transfected with
50 nM siRNA during 8 hours using TransIT-siQuest following
manufacturer’s instructions (Mirus, Madison, USA). Oligos were
obtained from Sigma-Genosys (Suffolk, UK). The oligo sequences
were as follows: unsilencing: GUAAGACACGACUUAUCGC;
mouse NOX4: CAAGAAGAUUGUUGGAUAA. The unsilen-
cing siRNA used was selected from previous works [22]. Specific
oligos with maximal knock-down efficiency were selected among
three different sequences for each gene.
Statistics
All data represented at least three experiments and expressed as
the mean 6 SEM. Differences between groups were compared
using either Student’s t test or one-way ANOVA associated with
the Dunnett’s test. Statistical significance was assumed when
p,0.05.
Results
Activation of the TGF-b/NOX4 pathway in fibrosis
development
Mdr22/2 mice represent a widely used model for experimental
liver fibrosis [16,17] and are characterized by chronic liver injury
and large periductal accumulation of MFBs. Similarly, Mdr22/2/
p19ARF2/2 double null mice [15] displayed a fibrotic phenotype
comparable to Mdr22/2 mice which allows, on one hand,
investigation of in vivo fibrosis development and, on the other hand,
isolation of MFBs for in vitro experiments that become immortal-
ized upon loss of p19ARF, a gene involved in the negative control
of cell cycle [15]. As observed in Mdr22/2 mice, Mdr22/2/
p19ARF2/2 mice developed spontaneous fibrosis characterized by
periductal accumulation of collagen and MFBs, as well as an
increased number of Kupffer cells (F4/80 positive) (Suppl. Fig. 1).
Importantly, these periductal changes were accompanied by
damage of the hepatic parenchyma and compensatory hepatocyte
proliferation, since we could not only detect increased apoptosis by
cleaved caspase-3, but also increased numbers of Ki67 positive
cells, (Fig. 1A). Fibrotic cells, easily recognized by their elongated
form, condensed nuclei and positive expression for alpha-Smooth
Muscle Actin (a-SMA) (Suppl. Fig. 1), stained for Ki67, but not for
apoptosis. Of note, dying hepatocytes were mostly detected in the
surrounding tissue of these fibrotic areas. Stat3Dhc/Mdr22/2 mice
represent a mouse model with conditional inactivation of Stat3 in
hepatocytes and cholangiocytes of Mdr22/2 mice [18]. Loss of the
hepatoprotective transcription factor Stat3 strongly aggravated
liver injury and fibrosis of the Mdr22/2 fibrotic phenotype (Suppl.
Fig. 2) leading to premature lethality. The compensatory
hepatocyte proliferation due to parenchymal liver damage was
severely reduced in this model (Suppl. Fig. 2, Fig. 1B).
Previous reports have indicated that several profibrotic genes
are up-regulated at early stages of fibrosis development in Mdr22/
2 mice, highlighting the major pro-fibrotic cytokine, TGF-b [24].
In agreement with these previous results, we found that both TGF-
b and its downstream signal molecule, phospho-Smad2, were
increased during fibrosis development in both animal models as
analyzed by immunohistochemistry (Fig. 2 and Suppl. Fig. 3).
Phospho-Smad2 staining intensity was higher at 2 weeks and
decreased over time, inversely correlating with Smad7 level, a
TGF-b pathway inhibitor. Importantly, NOX4 level was also
found elevated in these fibrosis models in both hepatocytes and
fibroblastoid cells. In the case of hepatocytes, NOX4 expression
was more intense in those cells surrounding the MFBs area
(Fig. 3A), which was coincident with the regions showing positive
cells for cleaved caspase-3 (Suppl. Fig. 4). Interestingly, these
observations were corroborated in a model of chemically-induced
fibrosis by CCl4 injection (Suppl. Fig. 5). CCl4 model has been
widely used as an experimental model of chronic damage to the
liver that produces fibrogenesis and may mimic the situation of
human chronic liver diseases. These data together suggest that
changes in the expression of NOX4 occur in different experimen-
tal animal models of hepatic fibrosis.
Since lack of p19ARF allows the culture of spontaneously
immortalized cells, we isolated and cultured both HSC in an
inactive state from p19ARF2/2 non fibrotic livers and activated
MFB from Mdr22/2/p19ARF2/2 fibrotic livers, as described in
the Materials and Methods section. These MFB, which have
suffered the activation process in vivo during spontaneous fibrosis
development in Mdr22/2/p19ARF2/2mice, showed increased
expression of NOX1, NOX2 and NOX4 at the mRNA level when
compared to p19ARF2/2 inactive HSC (Fig. 3B–D, left graphs).
Thus, these results suggest that these NOX isoforms may be
induced during the HSC activation process. In addition, and
corroborating the results at the tissue level, immortalized
hepatocytes showed very high NOX4 expression when compared
to HSC or MFB, which was further up-regulated when they were
treated with TGF-b (Fig. 3B, right graph). NOX1 expression was
also predominantly expressed in hepatocytes, but was down-
regulated by TGF-b in in vitro experiments (Fig. 3C, right graph).
NOX2 was predominantly expressed in MFBs and was not
affected by TGF-b in hepatocytes (Fig. 3D).
Role of NOX4 in HSC activation and MFBs phenotype
maintenance
Since NOX4 seemed to increase during the transdifferentiation
process of HSC to MFBs and its role in this process is completely
Role of NOX4 in Liver Fibrosis
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unknown, we decided to focus our study on the potential role of
NOX4 in the in vitro activation of HSC with TGF-b. As expected,
TGF-b treatment induced HSC activation, featured by increase in
a-SMA levels and E-cadherin down-regulation, which was
accompanied by NOX1, NOX2 and NOX4 up-regulation
(Fig. 4A). In the absence of TGF-b, this activation was not
observed (Suppl. Fig. 6). Regulation of a-SMA at the protein level
correlated with parallel changes at the mRNA level, along with up-
regulation of vimentin and the extracellular matrix genes collagen
I and fibronectin (Fig. 4B). The same panel shows that all these
changes in gene expression induced by TGF-b were inhibited
when NOX4 was knocked-down in cultured HSC cells. Impor-
tantly, phenotypical changes induced by TGF-b during the
transdifferentiation process, such as morphological alterations
and increased expression and reorganization of a-SMA and
vimentin, were impaired when NOX4 was targeted knock-down
(Fig. 4C). No apparent changes in the viability of these cells were
observed in NOX4 deficient cells (results not shown).
Since TGF-b and NOX4 appeared to play a crucial role in the
activation of HSC, we next wondered if they could play a role in
the maintenance of the activated MFB phenotype. For this
purpose, firstly we treated isolated Mdr22/2/p19ARF2/2 MFBs
during 72 hours with LY364947, an inhibitor of the TGF-b
receptor I (TbRI), in in vitro experiments. As shown in Figure 5A,
inhibition of the TbRI reversed the MFB phenotype, measured as
expression of pro-fibrotic genes, which correlated with a decrease
in NOX4 mRNA levels. Importantly, this fact implicates plasticity
of the MFB phenotype suggesting that it is possible to reverse the
MFB activated state towards a more inactive HSC-like phenotype.
It is worthy to note that blocking the TGF-b pathway down-
Figure 1. Fibrosis development in Mdr22/2/p19ARF2/2 and Stat3Dhc/Mdr22/2mice is accompanied by hepatocellular proliferation
and apoptosis. Representative 60x histological sections of livers from control or 2 or 7 weeks-old Mdr22/2/p19ARF2/2 (A) and Stat3Dhc/Mdr22/2
mice (B): Ki67 (upper row) and cleaved caspase-3 (lower row). Inset: quantification of positive cells for each marker. Data represent the mean 6 SEM
of the number of positive cells in at least ten different fields. Student’s t test calculated versus control sections (*p,0.05; **p,0.01;***p,0.001).
doi:10.1371/journal.pone.0045285.g001
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regulated TGF-b expression, indicating the existence of an
autocrine positive feed-back loop implicated in the maintenance
of the MFB properties. In addition, as shown in Fig. 5B, NOX4
knock-down produced a similar change as the one found with the
TbRI inhibitor. Indeed, the expression of pro-fibrotic genes, as
well as a-SMA and vimentin expression and organization, were
significantly diminished when NOX4 was knocked-down, cells
acquiring an HSC-like morphology (Fig. 5C). Furthermore,
desmin expression, as a marker of activated stellate cells, decreased
when NOX4 was knocked-down, correlating with the reversion of
MFB phenotype. However, NOX4 silencing was unable to inhibit
the expression of either TGF-b or its receptor (Fig. 5B, 5D), and it
did not alter Smad2/3 phosphorylation status (Fig. 5D).
These results together suggest that NOX4 acts downstream
TGF-b and controls the expression of different pro-fibrotic genes;
however, autocrine expression of the cytokine in MFB, and
activation of its downstream immediate signals, i.e., Smads, seems
to be independent of NOX4.
It is interesting to point out that NOX4 expression at the
mRNA level in both HSC and MFB was much higher than the
expression of the other isoforms NOX1 and NOX2 (50-fold
higher than NOX2 and 25-fold higher than NOX1 in hepato-
cytes; 80-fold higher than NOX2 and 60-fold higher than NOX1
in HSC: Suppl. Fig. 7), which may explain why neither NOX1 nor
NOX2 replaces NOX4 function.
Role of NOX4 in hepatocytes
Finally, we decided to study the putative role of NOX4 in TGF-
b-induced effects in hepatocytes. As shown in Fig. 6A, NOX4
expression was significantly up-regulated reaching the maximum
mRNA levels at 12 h and the maximum protein level at 24–
48 hours upon TGF-b treatment. As we and others have
previously reported in several experimental models, induction of
apoptosis by TGF-b was impaired when NOX4 was knocked-
down (Fig. 6B). These in vitro data support the immunohistochem-
istry studies, where elevated NOX4 expression seemed to correlate
with the areas of higher apoptosis of hepatocytes (Suppl. Fig 4).
Interestingly, supplementation of cell culture medium with either
antioxidants or a general inhibitor of NADPH oxidases (DPI)
blocked TGF-b-induced ROS production and caspase-3 activa-
tion in hepatocytes (Suppl. Fig. 8A, B). In a similar way, a
permeable form of GSH and DPI also attenuated changes in gene
expression addressed by TGF-b in HSC (Suppl. Fig. 8C),
highlighting the relevant role played by ROS in these processes.
We have previously reported that some liver cells are able to
impair the pro-apoptotic effects of TGF-b and undergo EMT,
characterized by cytoskeleton rearrangement and changes in gene
expression leading to a mesenchymal phenotype with up-
regulation of Snail, vimentin and a-SMA and loss of E-cadherin
expression [21,25]. In view of the results regarding apoptosis, we
next wondered whether NOX4 could be mediating TGF-b-
induced EMT in vitro. NOX4 knock-down did not influence TGF-
b-induced cytoskeletal changes, neither affected the expression of
several EMT-related genes (Fig. 6C, D). In summary, NOX4 is
Figure 2. TGF-b pathway is activated at early stages of fibrosis in Mdr22/2/p19ARF2/2 and Stat3Dhc/Mdr22/2 mice. 60x histological
sections of livers from control or 2 or 7 weeks-old Mdr22/2/p19ARF2/2 (A) and Stat3Dhc/Mdr22/2 mice (B) were stained with phospho-Smad2 or
Smad7 and the number of positive cells was quantified. Left graph: positive nuclei for phospho-Smad2 with low or high signal intensity. Right graph:
positive nuclei for Smad7. Data represent the mean 6 SEM of cells in at least ten different fields. Student’s t test calculated versus control sections
(*p,0.05; **p,0.01;***p,0.001).
doi:10.1371/journal.pone.0045285.g002
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Figure 3. NOX4 expression is increased concomitant with fibrosis development in Mdr22/2/p19ARF2/2 and Stat3Dhc/Mdr22/2 mice.
(A) Representative 60x photographs from NOX4 immunohistochemistry performed in control or 2 or 7 weeks-old livers. (B, C, D) Real time PCR of
NOX4, NOX1 or NOX2. Left: comparison of cultures of inactive stellate cells (HSC) isolated from p19ARF2/2 mice, in vivo activated myofibroblats (MFB)
isolated from fibrotic Mdr22/2/p19ARF2/2 livers and wild type immortalized hepatocytes (Hep) (see Materials and Methods section). Right:
immortalized hepatocytes treated or not with 2 ng/ml TGF-b. Data represent the mean 6 SEM of three independent experiments, and were
calculated relative to HSC (left) or untreated hepatocytes (right) respectively, which were given an arbitrary value of 1. Student’s t test calculated
versus HSC cells in the left column (*p,0.05; **p,0.01) or untreated hepatocytes in the right column (**p,0.01).
doi:10.1371/journal.pone.0045285.g003
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Figure 4. NOX4 knock-down inhibits TGF-b-dependent HSC activation. (A) p19ARF2/2 HSC cells at early passages were treated for the
indicated times with 2 ng/ml TGF-b and a Western blot of total extracts was performed. b-actin was used as loading control. Additional information
to this experiment is presented in Suppl. Fig. 6, where the expression of the different proteins in HSC cultured for 24, 48 and 72 h in the absence of
treatments is shown, as well as densitometric analysis of the Western blots. In (B) and (C), p19ARF2/2 HSC cells were transfected with either an
unsilencing siRNA (uns siRNA) or a specific siRNA for NOX4 (NOX4 siRNA) and then treated or not with 2 ng/ml TGF-b during 48 hours, when it was
performed: (B) RT-PCR of NOX4, a-SMA (Acta2), vimentin (vim), fibronectin (Fn1) and collagen I (Col1a1); (C) immunofluorescence images of F-actin, a-
SMA and vimentin. A representative image for each RT-PCR (B) or immunofluorescence staining (C) is shown. 18S was used as loading control in B.
Since HSC are very sensitive to serum deprivation, all experiments were carried out in the presence of 10% FBS.
doi:10.1371/journal.pone.0045285.g004
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Figure 5. NOX4 downstream autocrine TGF-b is necessary to maintain the activated phenotype of cultured Mdr22/2/p19ARF2/2
MFB. MFB isolated from fibrotic Mdr22/2/p19ARF2/2 livers were used. (A) Real time PCR of Mdr22/2/p19ARF2/2 MFB treated for 72 hours with 10 mM
LY36494 (TRbI inhibitor): NOX4, a-SMA (Acta2), vimentin (vim), fibronectin (Fn1), collagen I (Col1a1) and TGF-b1 (Tgfb1). In B–D, Mdr2
2/2/p19ARF2/2
MFB were transfected with either an unsilencing siRNA (uns siRNA) or a specific siRNA for NOX4 (NOX4 siRNA) for 72 hours, when it was performed:
(B) Real time PCR of the indicated genes. (C) Immunofluorescence staining of F-actin, a-SMA and vimentin. (D) Western blot of total lysates. b-actin
was used as loading control. Data represent the mean6 SEM of three to six independent experiments, and were calculated relative to untreated MFB
(A) or unsilencing-transfected cells (B) (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0045285.g005
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Figure 6. NOX4 is required for apoptosisbut not necessary for the EMT process, induced by TGF-b in hepatocytes. (A) TGF-b induces
NOX4 expression in hepatocytes. NOX4 transript and protein levels were determined by Real time-PCR (upper panel) and western blot (lower panel),
respectively, at the indicated times of treatment with 2 ng/ml TGF-b. In B–D, immortalized hepatocytes were transfected with either an unsilencing
siRNA (uns siRNA) or a specific siRNA for NOX4 (NOX4 siRNA), serum-depleted for 4 hours and, finally, treated or not with 2 ng/ml TGF-b. (B) Cell
death analysis: activation of caspase-3 activity at 16 hours, where the peak of maximal activation was found (upper graph); percentage of cells with
apoptotic nuclei at 48 h upon nuclear staining with DAPI (middle graph); loss in cell viability at 48 h (lower graph). Data represent the mean6 SEM of
three independent experiments. Student’s t test calculated comparing TGF-b-treated cells between the two conditions with the different siRNAs
(**p,0.01; ***p,0.001). (C) Fluorescence microscopy staining for F-actin and E-cadherin at 48 hours. (D) Representative RT-PCR of the indicated
genes after 3 h of treatment to observe the effects on Nox4 expression (upper panel) and 48 h of treatment to analyze the effects on EMT-related
genes (bottom panel). 18S was used as loading control.
doi:10.1371/journal.pone.0045285.g006
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implicated in apoptosis but not in the EMT process that TGF-b
induces in hepatocytes.
Up-regulation of TGF-b and NOX4 in human samples
from HCV infected patients
Since our in vivo and in vitro results in animal models pointed to a
crucial role for NOX4 in fibrosis development, we next studied the
situation in human samples. For this reason, we chose patients
suffering from different degrees of liver fibrosis associated to HCV
infection, who were classified as having mildly fibrotic livers (F0–
F2) or severely fibrotic and cirrhotic livers (F3/F4) (Table 1).
Comparing with samples from control livers, we performed real
time PCR determinations of the three isoforms of TGF-b and the
corresponding receptors, and also NOX1, NOX2 and NOX4. As
shown in Fig. 7, TGF-b1 shows a clear tendency to increase from
F0/F2 stages, showing significant enhanced levels in F3/F4
patients. TGF-b2 was also significantly increased in the F3/F4
stage (Fig. 7A). No relevant changes in the expression of their
receptors were observed. Interestingly, NOX1 expression did not
show any significant change (Fig. 7C, left graph), but NOX2 and
NOX4 were significantly up-regulated in fibrotic livers, being the
relative increase in NOX4 higher than that observed for NOX2
(Fig. 7C).
Discussion
Chronic liver disease often progresses to fibrosis and finally to
cirrhosis, which is a preneoplastic condition [1]. Thus far, there
are no direct therapies aimed at liver fibrosis reversal, therefore
innovative antifibrogenic approaches are needed [26]. Different
models of hepatic fibrosis have been used to study the molecular
Figure 7. TGF-b1 and 2, NOX2 and NOX4 are up-regulated in human samples from patients with HCV-derived fibrosis. Samples from
patients showing control livers (control; n = 10), low or mildly fibrotic livers (F0–F2; n = 16) or severely fibrotic and cirrhotic livers (F3/F4; n = 12). Real
time determination of TGF-b1(TGFB1), TGF-b2 (TGFB2), TGF-b3 (TGFB3) (A), TGFbRI and TGFbRII (TGFBR1, TGFBR2) (B), and NOX1, NOX2 and NOX4 (C).
Statistic was calculated using one-way ANOVA associated with Dunnett’s test.
doi:10.1371/journal.pone.0045285.g007
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pathogenesis of this disease. From these studies, several key
generalizations have been done [1]: i) TGF-b is the most potent
liver pro-fibrogenic cytokine; ii) oxidative stress induces liver
fibrosis; iii) blocking normal liver regeneration by massive
hepatocyte apoptosis turns out to be pro-fibrogenic. One of the
most studied mechanisms of fibrogenesis actually influenced by
ROS is myofibroblast activation. Previous reports and results
presented in this manuscript have revealed that stellate cell
transdifferentiation into myofibroblast is inhibited by antioxidants
[27,28]. NOX4 downstream TGF-b has been described as the
main mediator for myofibroblast activation in different organs
such as heart [12], lung [11], kidney [13] and diseased prostatic
stroma [14]. However, very few were known about the role of
NOX4 in liver fibrosis. Results presented here indicate that
induction of NOX4 occurs in three different animal models of
liver fibrosis and in chronic HCV infection in humans, associated
with activation of the TGF-b pathway, appearance of fibrotic
areas and hepatocyte proliferation and apoptosis. NOX4 may play
a key role in liver fibrosis development, downstream TGF-b, at
two different levels: i) in vitro experiments reveal that NOX4 is
required for both HSC activation and maintenance of the
activated phenotype in MFBs and ii) hepatocytes respond to
TGF-b by inducing NOX4 that is required for its pro-apoptotic
response, which might be relevant to blunt regeneration and
create a pro-fibrogenic microenvironment.
However, the role of NOX proteins in liver fibrogenesis is not
only circumscribed to NOX4. Thus, studies performed in
Nox12/2, Nox22/2 or p47phox2/2 mice have pointed out the
importance of NOX1 and NOX2 in fibrosis development
[5,29,30]. Our results indicate that expression of NOX4 at the
mRNA levels is much higher than those found for NOX1 and
NOX2 in HSCs and hepatocytes, and functions are not
redundant, since knock-down of NOX4 in these cells cause effects
that cannot be prevented by the other NOXes. It is possible that
each isoform plays differential roles in liver fibrosis. Indeed, it has
been suggested that NOX1 promotes myofibroblast proliferation
by PTEN inactivation to positively regulate an Akt/FOXO4/p27
signaling pathway [29]. NOX2, highly expressed in macrophages
and bone marrow-derived cells [8] may be acting in the process of
phagocytosis of dead hepatocytes [30]. NOX1 activity might also
contribute to the inflammatory process promoting COX-2
expression and prostaglandin synthesis in hepatocytes [31].
Interestingly, whereas the revised version of this manuscript was
being prepared, evidences for the role of dual NOX4/NOX1
pharmacological inhibitors in decreasing both the apparition of
fibrogenic markers and hepatocyte apoptosis in vivo, upon bile duct
ligation, were reported [32], highlighting the relevant role of
NOX1 and NOX4 in liver fibrosis and opening new perspectives
for its treatment.
Hepatic fibrosis has been considered as an irreversible process
but recent experimental and clinical data indicate that removal of
the pro-fibrotic agent or condition may reverse liver fibrosis [33].
Results presented in this manuscript suggest that either TbRI
inhibition or NOX4 silencing reverses the MFB phenotype,
decreasing the expression of extracellular matrix genes, such as
collagen I or fibronectin, down-regulating a-SMA and vimentin
expression and changing cell morphology, which loses myofibro-
blastic appearance. Since it has been recently proposed that
NOX4 modulates a-SMA and procollagen I (alpha1) expression in
pulmonary fibrosis by controlling activation of Smad2/3 [34], we
checked the effect of silencing NOX4 on TGF-b levels and
Smad2/3 phosphorylation. Our results have indicated that NOX4
clearly acts downstream TGF-b-independently from Smads
activation. It also has been described that NOX4 is critical for
maintenance of smooth muscle gene expression in vascular smooth
muscle cells [35], where ROS production impairs the TGF-b-
induced phosphorylation of Ser103 on serum response factor
(SRF) and reduces its transcriptional activity. Thus, NOX4 may
play an important role associated with the a-SMA phenotype,
being not only important in fibrotic processes, but also in
cardiovascular physiology.
We have previously described that liver cells respond to TGF-b
in vitro undergoing EMT [25,36]. The role of EMT is perhaps the
most intriguing and controversial of recent hypothesis on the
origin mechanisms of liver fibrosis [37]. Strong evidences indicate
that hepatocytes from transgenic animals that overexpress Snail (a
master gene involved in EMT through its capacity to repress E-
cadherin gene, among others) fully undergo EMT [38] and may
propagate liver fibrosis progression [39]. However, under normal
genetic background, data from different experimental approaches
in animals and humans show controversy [40]. Our results show
that EMT occurs in hepatocytes in vitro, but NOX4 is not required
for this process. However, NOX4 mediates TGF-b-induced cell
death that is prevented in the presence of antioxidants. In
agreement with these results, it has been recently proposed a role
for NOX4 in epithelial cell death during development of
bleomycin-induced lung fibrosis [41]. Using a model of NOX4-
deficient mice, authors demonstrated that these animals were
resistant to fibrosis due to the abrogation of TGF-b-induced
apoptosis in epithelial cells. Prevention of apoptosis impaired
fibrosis development, although inflammation was comparable to
wild-type. A similar situation may occur in liver fibrosis, where
engulfment of apoptotic bodies by HSC contributes to induce their
activation [7]. Indeed, hepatocyte apoptosis not only would
facilitate fibrosis through blocking liver regeneration, but it could
play an active role. In this line of evidence, inhibiting apoptosis
decreased the liver profibrogenic response [7,42]. Additionally to
the crucial role of NOX4 in TGF-b-induced cell death, recent
Table 1. Demographic, virological and histopathological
characteristics of patients with chronic hepatitis C.
Age (yr) (Median and range) 46 (31–67)
Gender (M/F) 17/11
Baseline Viral load (6103 IU/ml) (Mean 6 SD) 1.3662.05
Genotype distribution (%) Ia 7.14
Ib 75.00
II 3.57
III 14.28
Activity distribution (n, %) (METAVIR) 0 0 (0)
1 11 (39.28)
2 14 (50.00)
3 3 (10.71)
4 0 (0)
Fibrosis distribution (n, %) (METAVIR) 0 1 (3.57)
1 11 (39.28)
2 4 (14.28)
3 7 (25.00)
4 5 (17.85)
Tissue of liver biopsies from 28 patients with chronic hepatitis C in different
stages of liver fibrosis was examined for the gene expression analysis shown in
Fig. 7.
doi:10.1371/journal.pone.0045285.t001
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results indicate that it may be also required for apoptosis induced
by other stimuli in liver cells, such as FasL and TNF-a/
actinomycin D [32].
Finally, the finding that NOX4 is induced during the
progression of a HCV disease reinforces the hypothesis of a role
for NOX4 in human liver fibrosis. The magnitude of NOX4 up-
regulation is higher than that observed for its co-partner NOX2
and, interestingly, we could not find any significant change in the
expression of NOX1. NOX4 induction is observed at early stages
of the disease when increases of TGF-b1 and 2 are not significant
yet. This could be mediated by release of inflammatory signals
that, indeed, up-regulate NOX4 in hepatocytes [31]. Further-
more, different reports support that HCV induces a persistent
elevation and increased nuclear localization of NOX4 in in vitro
assays in hepatocytes, a process that was TGF-b-dependent
[43,44]. Collectively, all these data provide evidences to propose
that HCV-induced NOX4 may contribute to ROS production
and may be related to HCV-induced liver disease. Results
presented in this manuscript support that NOX4 could play an
essential role inducing activation of stellate cells and apoptosis of
hepatocytes under these conditions of human disease, contributing
to the development of liver fibrosis.
Development of first-in-class series of NOX4 inhibitors for the
potential treatment of fibrotic diseases, cardiovascular and
metabolic syndromes is in progress [45]. Liver fibrosis might be
considered for future clinical trials with these drugs. Likewise,
ROS and NOX4 induced by TGF-b have proved to be
therapeutic targets of polyenylphosphatidylcholine in the suppres-
sion of human stellate cell activation [46]. Since NOX4 is mainly
expressed in hepatocytes and HSC [8], according to the results
presented in this manuscript, NOX4 inhibitors would specifically
prevent HSC activation and hepatocytes cell death, without
altering the role of other NOXes, such as NOX2, which might
play defense function in Kupffer cells. In advanced stages of the
disease, NOX4 inhibitors might be able to reverse the fibrotic
phenotype acting on MFBs. Furthermore, and not less important,
we demonstrate that silencing NOX4 prevents fibrogenesis but has
no effect on TGF-b-mediated Smads phosphorylation. Indeed, the
use of pharmacological drugs targeting NOX4 expression/
activation would inhibit fibrogenesis without blocking other
beneficial effects of TGF-b, such as growth inhibition in the
epithelial cells, which prevents initiation of a pre-neoplastic stage.
In summary, here we show that NOX4 expression is elevated in
the livers of experimental in vivo models of liver fibrosis and in
patients with chronic HCV-derived infection, increasing along the
fibrosis degree. NOX4, downstream TGF-b pathway, would play
a role in the acquisition and maintenance of the MFB phenotype,
as well as in mediating death of hepatocytes, which provokes
inflammation and facilitates extracellular matrix deposit.
Supporting Information
Figure S1 Fibrosis development in Mdr22/2/p19ARF2/2
mice. Representative histological sections of livers from control or
2 or 7 weeks-old Mdr22/2/p19ARF2/2 mice. H&E, trichrome C
staining and immunohistochemistru of F4/80, a-SMA, E-cadherin
(E-cad) or vimentin (Vim) are shown.
(TIF)
Figure S2 Fibrosis development in Stat3Dhc/Mdr22/2
mice. Representative histological sections of livers from control or
2 or 7 weeks-old Stat3Dhc/Mdr22/2 mice. H&E, trichrome C
staining and immunohistochemistru of F4/80, a-SMA, E-cadherin
(E-cad) or vimentin (Vim) are shown.
(TIF)
Figure S3 TGF-b pathway is activated in Mdr22/2/
p19ARF2/2 and Stat3Dhc/Mdr22/2 mice. Immunohisto-
chemistry analysis of TGF-b, phospho-Smad2 or Smad7 in
Mdr22/2/p19ARF2/2 (A) and Stat3Dhc/Mdr22/2 mice (B).
(TIF)
Figure S4 NOX4 expression in hepatocytes correlates
with activation of caspase-3 in fibrotic tissues from
Mdr22/2/p19ARF2/2mice. Immunohistochemistry analysis of
NOX4 and the active form (cleaved) of caspase-3 in: hepatocytes
around the vascular (up) or fibrotic (bottom) areas (A); two serial
sections showing coincidence in the expression of both proteins in
the same cells (B).
(TIF)
Figure S5 NOX4 expression is increased concomitant
with fibrosis development in CCl4 injection. Liver samples
were collected and processed for immunohistochemical analysis.
Representative results for NOX4, cleaved caspase-3 and Ki67 are
shown.
(TIF)
Figure S6 Additional information to Figure 4. Expression
of the different proteins analyzed in the Western blot of Figure 4A
in HSC cells cultures for 24, 48 and 72 h in the absence of
treatments (A). Quantitation of the intensity of the bands through
densitometric analysis, relative to loading (b-actin) is shown above
each band. A similar quantification approach for Western blot in
Figure 4A is shown in B.
(TIF)
Figure S7 Role of NOX4 knock-down with specific
siRNA on the expression of NOX4, NOX2 and NOX1 in
HSC (A) and MFB (B). p19ARF2/2 HSC cells (A) and
Mdr22/2/p19ARF2/2 MFB (B) were transfected with either an
unsilencing siRNA (uns. siRNA) or a specific siRNA for NOX4
(NOX4 siRNA) as described in Figs. 4 and 5, respectively. In the
case of HSC (A), cells were either not treated or treated with TGF-
b (2 ng/ml), as indicated in the figure. Data shown correspond to
the real-time PCR analysis of the mRNA levels of NOX4, NOX2
and NOX1, which were calculated relative to 18S expression. In
order to compare the expression level among the different
isoforms, we gave an arbitrary value of 1 to NOX4 expression
under basal conditions in both HSC (A) and MFB (B), and all the
data are referred to this value. Mean 6 S.E.M. is shown and the
specific value of the mean detailed above each bar.
(TIF)
Figure S8 Role of antioxidants (GEE and BHA) or a
NADPH oxidase inhibitor (DPI) on the effects of TGF-b
on ROS production and apoptosis in hepatocytes (A and
B, respectively) and activation of HSC (C). Cells were pre-
incubated during 30 min with 1 mM DPI, 2 mM GEE or
200 mM BHA, as indicated in each figure, before adding 2 ng/ml
of TGF-b. The same concentrations of the agents were
maintained during all the TGF-b treatment. A. After 3 h of
treatment in hepatocytes, intracellular content of ROS was
analyzed through fluorimetric assay as detailed in the Materials
and Methods section. Data represent the mean 6 S.E.M. of 3
independent experiments in triplicate and are referred to the
value in untreated cells (100%). B. After 16 h of treatment in
hepatocytes, proteins were collected for caspase-3 analysis. Data
represent the mean 6 S.E.M. of 3 independent experiments in
duplicate and are expressed as arbitrary units per hour and per
microgram of protein. C. After 48 h of treatment in HSC, RNA
was collected for analysis of expression by RT-PCR of the genes
Role of NOX4 in Liver Fibrosis
PLOS ONE | www.plosone.org 12 September 2012 | Volume 7 | Issue 9 | e45285
detailed in the figure. A representative experiment out of 3 is
shown.
(TIF)
Table S1 Mouse primer sequences used for semiquan-
titative PCR.
(DOC)
Table S2 Mouse and human primer sequences used for
quantitative real-time PCR.
(DOC)
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